The executive medical director at AbbVie discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.
|Slideshows|April 2, 2018
Parkinson Disease: Recent Articles You May Have Missed
Author(s)Natalie Timoshin
Parkinson disease articles published in 2018 reveal deeper dives into factors that include the impact of sleep and fatigue on symptoms.
Advertisement
Advertisement
Related to this article
Alnylam Pharmaceuticals reported initial Phase 1b findings showing brezosiran reduced cerebrospinal fluid mutant huntingtin levels by a mean of 60% to 64% at 3 months, with plans for a pivotal study in 2027.
The FDA accepted uniQure's biologics license application for ifezuntirgene inilparvovec and granted it Priority Review, setting a target action date of May 1, 2027.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Brezosiran Demonstrates Mutant Huntingtin Reduction in Phase 1b Huntington Disease Study
2
Alzheimer Agent Sabirnetug Misses Primary Endpoint, Acumen Halts Development
3
AL-S Pharma Details Planned Phase 3 Trial Design for AP-101 in ALS
4
FDA Grants Priority Review to Huntington Disease Gene Therapy BLA
5